260 related articles for article (PubMed ID: 22479369)
21. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.
Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R
Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267
[TBL] [Abstract][Full Text] [Related]
22. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
23. Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy.
Zhang ZY; Tian X; Wu R; Liang Y; Jin XY
Asian Pac J Cancer Prev; 2012; 13(6):2583-6. PubMed ID: 22938424
[TBL] [Abstract][Full Text] [Related]
24. Association between genetic polymorphisms in XPD and XRCC1 genes and risks of non-small cell lung cancer in East Chinese Han population.
Du Y; He Y; Mei Z; Qian L; Shi J; Jie Z
Clin Respir J; 2016 May; 10(3):311-7. PubMed ID: 25308691
[TBL] [Abstract][Full Text] [Related]
25. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
[TBL] [Abstract][Full Text] [Related]
26. Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.
Nairuz T; Bushra YU; Kabir Y
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3809-3815. PubMed ID: 34967559
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.
Qin Q; Zhang C; Yang X; Zhu H; Yang B; Cai J; Cheng H; Ma J; Lu J; Zhan L; Liu J; Liu Z; Xu L; Sun X
PLoS One; 2013; 8(11):e79864. PubMed ID: 24260311
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.
Wei SZ; Zhan P; Shi MQ; Shi Y; Qian Q; Yu LK; Song Y
Med Oncol; 2011 Mar; 28(1):315-21. PubMed ID: 20143185
[TBL] [Abstract][Full Text] [Related]
30. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
[TBL] [Abstract][Full Text] [Related]
31. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
32. Gene polymorphism of DNA repair gene X-ray repair cross complementing group 1 and xeroderma pigmentosum group D and environment interaction in non-small-cell lung cancer for Chinese nonsmoking female patients.
Wang L; Wang LL; Shang D; Yin SJ; Sun LL; Wang XY; Ji HB
Kaohsiung J Med Sci; 2019 Jan; 35(1):39-48. PubMed ID: 30844146
[TBL] [Abstract][Full Text] [Related]
33. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Li Y; Huang XE; Jin GF; Shen HB; Xu L
Asian Pac J Cancer Prev; 2011; 12(3):739-42. PubMed ID: 21627375
[TBL] [Abstract][Full Text] [Related]
34. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy.
Zhao X; Wang X; Wu W; Gao Z; Wu J; Garfield DH; Wang H; Wang J; Qian J; Li H; Jin L; Li Q; Han B; Lu D; Bai C
Cancer; 2012 Jul; 118(14):3587-98. PubMed ID: 22072145
[TBL] [Abstract][Full Text] [Related]
36. Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Joerger M; Burgers SA; Baas P; Smit EF; Haitjema TJ; Bard MP; Doodeman VD; Smits PH; Vincent A; Huitema AD; Beijnen JH; Schellens JH
Cancer; 2012 May; 118(9):2466-75. PubMed ID: 22031394
[TBL] [Abstract][Full Text] [Related]
37. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
Jiang YH; Xu XL; Ruan HH; Xu WZ; Li D; Feng JG; Han QB; Mao WM
Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796
[TBL] [Abstract][Full Text] [Related]
38. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
39. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
Gan Y; Li XR; Chen DJ; Wu JH
Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]